259 related articles for article (PubMed ID: 26961176)
41. Inhibition of endothelial cell functions and of angiogenesis by the metastasis inhibitor NAMI-A.
Vacca A; Bruno M; Boccarelli A; Coluccia M; Ribatti D; Bergamo A; Garbisa S; Sartor L; Sava G
Br J Cancer; 2002 Mar; 86(6):993-8. PubMed ID: 11953835
[TBL] [Abstract][Full Text] [Related]
42. Ruthenium metalation of proteins: the X-ray structure of the complex formed between NAMI-A and hen egg white lysozyme.
Messori L; Merlino A
Dalton Trans; 2014 Apr; 43(16):6128-31. PubMed ID: 24553967
[TBL] [Abstract][Full Text] [Related]
43. Combined therapy of the antimetastatic compound NAMI-A and electroporation on B16F1 tumour cells in vitro.
Bicek A; Turel I; Kanduser M; Miklavcic D
Bioelectrochemistry; 2007 Nov; 71(2):113-7. PubMed ID: 17602896
[TBL] [Abstract][Full Text] [Related]
44. Modification of cell cycle and viability of TLX5 lymphoma in vitro by sulfoxide-ruthenium compounds and cisplatin detected by flow cytometry.
Capozzi I; Clerici K; Cocchietto M; Salerno G; Bergamo A; Sava G
Chem Biol Interact; 1998 May; 113(1):51-64. PubMed ID: 9630847
[TBL] [Abstract][Full Text] [Related]
45. Free exchange across cells, and echistatin-sensitive membrane target for the metastasis inhibitor NAMI-A (imidazolium trans-imidazole dimethyl sulfoxide tetrachlororuthenate) on KB tumor cells.
Frausin F; Scarcia V; Cocchietto M; Furlani A; Serli B; Alessio E; Sava G
J Pharmacol Exp Ther; 2005 Apr; 313(1):227-33. PubMed ID: 15579494
[TBL] [Abstract][Full Text] [Related]
46. Cocultures of metastatic and host immune cells: selective effects of NAMI-A for tumor cells.
Bacac M; Vadori M; Sava G; Pacor S
Cancer Immunol Immunother; 2004 Dec; 53(12):1101-10. PubMed ID: 15221285
[TBL] [Abstract][Full Text] [Related]
47. Ruthenium anticancer agent KP1019 binds more tightly than NAMI-A to tRNA
Dwyer BG; Johnson E; Cazares E; McFarlane Holman KL; Kirk SR
J Inorg Biochem; 2018 May; 182():177-183. PubMed ID: 29501978
[TBL] [Abstract][Full Text] [Related]
48. A spectroscopic study of the reaction of NAMI, a novel ruthenium(III)anti-neoplastic complex, with bovine serum albumin.
Messori L; Orioli P; Vullo D; Alessio E; Iengo E
Eur J Biochem; 2000 Feb; 267(4):1206-13. PubMed ID: 10672032
[TBL] [Abstract][Full Text] [Related]
49. Lack of In vitro cytotoxicity, associated to increased G(2)-M cell fraction and inhibition of matrigel invasion, may predict In vivo-selective antimetastasis activity of ruthenium complexes.
Zorzet S; Bergamo A; Cocchietto M; Sorc A; Gava B; Alessio E; Iengo E; Sava G
J Pharmacol Exp Ther; 2000 Dec; 295(3):927-33. PubMed ID: 11082425
[TBL] [Abstract][Full Text] [Related]
50. Ruthenium anticancer drugs and proteins: a study of the interactions of the ruthenium(III) complex imidazolium trans-[tetrachloro(dimethyl sulfoxide)(imidazole)ruthenate(III)] with hen egg white lysozyme and horse heart cytochrome c.
Casini A; Mastrobuoni G; Terenghi M; Gabbiani C; Monzani E; Moneti G; Casella L; Messori L
J Biol Inorg Chem; 2007 Nov; 12(8):1107-17. PubMed ID: 17680283
[TBL] [Abstract][Full Text] [Related]
51. RNA-seq analysis of the whole transcriptome of MDA-MB-231 mammary carcinoma cells exposed to the antimetastatic drug NAMI-A.
Bergamo A; Gerdol M; Lucafò M; Pelillo C; Battaglia M; Pallavicini A; Sava G
Metallomics; 2015 Oct; 7(10):1439-50. PubMed ID: 26338673
[TBL] [Abstract][Full Text] [Related]
52. Biological role of adduct formation of the ruthenium(III) complex NAMI-A with serum albumin and serum transferrin.
Bergamo A; Messori L; Piccioli F; Cocchietto M; Sava G
Invest New Drugs; 2003 Nov; 21(4):401-11. PubMed ID: 14586207
[TBL] [Abstract][Full Text] [Related]
53. IL-1β promotes transendothelial migration of PBMCs by upregulation of the FN/α
Labus J; Wöltje K; Stolte KN; Häckel S; Kim KS; Hildmann A; Danker K
Exp Cell Res; 2018 Dec; 373(1-2):99-111. PubMed ID: 30342992
[TBL] [Abstract][Full Text] [Related]
54. Critical role of aquaporin 3 on growth of human esophageal and oral squamous cell carcinoma.
Kusayama M; Wada K; Nagata M; Ishimoto S; Takahashi H; Yoneda M; Nakajima A; Okura M; Kogo M; Kamisaki Y
Cancer Sci; 2011 Jun; 102(6):1128-36. PubMed ID: 21401805
[TBL] [Abstract][Full Text] [Related]
55. In vitro cell cycle arrest, in vivo action on solid metastasizing tumors, and host toxicity of the antimetastatic drug NAMI-A and cisplatin.
Bergamo A; Gagliardi R; Scarcia V; Furlani A; Alessio E; Mestroni G; Sava G
J Pharmacol Exp Ther; 1999 Apr; 289(1):559-64. PubMed ID: 10087050
[TBL] [Abstract][Full Text] [Related]
56. Synthesis and X-ray Structural Analysis of the Ruthenium(III) Complex Na[trans-RuCl4(DMSO) (PyrDiaz)], the Diazene Derivative of Antitumor NAMI-Pyr.
Vajs J; Pevec A; Gazvoda M; Urankar D; Goreshnik E; Polanc S; Košmrlj J
Acta Chim Slov; 2017 Dec; 64(4):763-770. PubMed ID: 29318318
[TBL] [Abstract][Full Text] [Related]
57. The Deceptively Similar Ruthenium(III) Drug Candidates KP1019 and NAMI-A Have Different Actions. What Did We Learn in the Past 30 Years?
Alessio E; Messori L
Met Ions Life Sci; 2018 Feb; 18():. PubMed ID: 29394024
[TBL] [Abstract][Full Text] [Related]
58. Influence of chemical stability on the activity of the antimetastasis ruthenium compound NAMI-A.
Sava G; Bergamo A; Zorzet S; Gava B; Casarsa C; Cocchietto M; Furlani A; Scarcia V; Serli B; Iengo E; Alessio E; Mestroni G
Eur J Cancer; 2002 Feb; 38(3):427-35. PubMed ID: 11818210
[TBL] [Abstract][Full Text] [Related]
59. Role of focal adhesion kinase and phosphatidylinositol 3'-kinase in integrin fibronectin receptor-mediated, matrix metalloproteinase-1-dependent invasion by metastatic prostate cancer cells.
Zeng ZZ; Jia Y; Hahn NJ; Markwart SM; Rockwood KF; Livant DL
Cancer Res; 2006 Aug; 66(16):8091-9. PubMed ID: 16912186
[TBL] [Abstract][Full Text] [Related]
60. A Key Regulator of Cell Adhesion: Identification and Characterization of Important
Hang Q; Isaji T; Hou S; Wang Y; Fukuda T; Gu J
Mol Cell Biol; 2017 May; 37(9):. PubMed ID: 28167607
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
